Compositions comprising SIA for the treatment of diabetes
First Claim
1. An isolated and stable supramolecular insulin assembly (SIA) useful as a protein therapeutic for the treatment of metabolic disorders selected from the group consisting of type 1, type 2 diabetes mellitus and complications thereof, wherein said assembly comprises insoluble and aggregated oligomeric form of insulin and wherein said assembly is protease resistant, exhibits no binding to Congo Red, has both α
- -helical and β
-sheet components, and releases biologically active insulin monomers in vitro or in vivo.
2 Assignments
0 Petitions
Accused Products
Abstract
A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.
14 Citations
34 Claims
-
1. An isolated and stable supramolecular insulin assembly (SIA) useful as a protein therapeutic for the treatment of metabolic disorders selected from the group consisting of type 1, type 2 diabetes mellitus and complications thereof, wherein said assembly comprises insoluble and aggregated oligomeric form of insulin and wherein said assembly is protease resistant, exhibits no binding to Congo Red, has both α
- -helical and β
-sheet components, and releases biologically active insulin monomers in vitro or in vivo. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
- -helical and β
Specification